Brain-Computer Interfaces: An Overview
BCIs translate neural activity into device control — and increasingly, write information back into the brain. The field is moving from laboratory to clinic, with the first commercial deployments now in regulated trials.
Key facts
- Cochlear implants — the most successful BCI in history — have been received by over 1 million people.
- Utah arrays have been used in humans since 2004 (BrainGate).
- Speech BCIs now exceed 60–80 words per minute in clinical trials.
- Synchron's Stentrode is implanted via blood vessels, requiring no open-brain surgery.
- DBS is FDA-approved for at least 5 conditions globally.
Recording Modalities
BCIs span non-invasive (EEG, fNIRS, MEG), minimally invasive (ECoG, endovascular stentrodes), and fully invasive (Utah arrays, Neuralink threads, Paradromics Connexus, Neuropixels) approaches. Bandwidth, signal quality, longevity, and surgical risk trade off sharply.
Non-invasive scales easily but resolves only coarse activity; invasive resolves single-unit spikes but raises biocompatibility and surgical-risk barriers.
Neural Decoding
Modern decoders use recurrent and transformer architectures to map neural population activity to cursor control, text, robotic limbs, or synthesized speech. Calibration is now minutes, not hours, thanks to transfer learning and subject-general foundation models.
State-of-the-art speech BCIs (Willett et al. Nature 2023; Metzger et al. Nature 2023) exceed 60–80 words per minute in people with paralysis.
Writing to the Brain
Therapeutic stimulation — DBS for movement disorders, cochlear implants for hearing, retinal implants for vision, spinal stimulators for paralysis — represents the most mature 'write' modality.
High-resolution sensory restoration and information write-in remain harder than reading; the brain's noise tolerance for spurious signals is low.
Clinical Applications
Restoration of communication in ALS and locked-in syndrome, motor control for paralysis (BrainGate, Synchron, Neuralink), vision restoration (Second Sight legacy, Science Corp), hearing restoration (cochlear implants — the most successful BCI in history with 1M+ recipients), and DBS for Parkinson's, essential tremor, dystonia, OCD, and depression.
Regulation and Oversight
FDA Investigational Device Exemptions govern early human trials. EU MDR, Japan's PMDA, and UK MHRA have parallel frameworks.
Patient selection, informed consent (especially for explant), and long-term device support are dominant ethical issues — particularly given the bankruptcy of past BCI vendors (Second Sight).
Frequently asked
Can BCIs read my thoughts?
+
No — current systems decode specific motor or language outputs the user actively intends to produce, not arbitrary thoughts. Mental privacy concerns are real for the future, not the present.
How long do BCIs last?
+
Implanted electrodes degrade over months to years due to gliosis and material fatigue. Improving longevity is one of the field's central research questions.
Who's a candidate for a BCI today?
+
People with severe paralysis, ALS, or locked-in syndrome enrolled in clinical trials. Broader indications are years to decades away.
Sources & further reading
Continue in this series
Industry
Neuralink, Synchron, and the BCI Industry
Therapeutics
Neural Implants and Stimulation
Frontier
Memory Prosthetics and Cognitive Augmentation
Ethics
Neurorights and the Ethics of Reading the Brain
Outlook
The Future of Brain-Computer Interfaces